Pyrimidine series PROTACs 9(GlaxoSmithKline)(Pyrimidine series PROTACs 9(GlaxoSmithKline))

概要

基本信息

药物类型

蛋白水解靶向嵌合体（PROTAC）

别名-

靶点

JAK1 x JAK2

作用机制

JAK1抑制剂(酪氨酸蛋白激酶JAK1抑制剂)、JAK2抑制剂(酪氨酸蛋白激酶JAK2抑制剂)

治疗领域-

在研适应症-

非在研适应症-

原研机构

GSK Plc

在研机构

GSK Plc

University of Strathclyde

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构/序列

分子式C47H59ClF2N10O9S

InChIKeyOOGRLHGJCRPASG-YTKUFENASA-N

CAS号-

关联

100 项与 Pyrimidine series PROTACs 9(GlaxoSmithKline) 相关的临床结果

登录后查看更多信息

100 项与 Pyrimidine series PROTACs 9(GlaxoSmithKline) 相关的转化医学

登录后查看更多信息

100 项与 Pyrimidine series PROTACs 9(GlaxoSmithKline) 相关的专利（医药）

登录后查看更多信息

1

项与 Pyrimidine series PROTACs 9(GlaxoSmithKline) 相关的文献（医药）

2015-11-12·Federal register

Schedules of Controlled Substances: Placement of Eluxadoline Into Schedule IV. Final rule.

Article

With the issuance of this final rule, the Administrator of the Drug Enforcement Administration places the substance 5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid (eluxadoline), including its salts, isomers, and salts of isomers, into schedule IV of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act which requires that such actions be made on the record after opportunity for a hearing through formal rulemaking. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule IV controlled substances on persons who handle (manufacture, distribute, dispense, import, export, engage in research, conduct instructional activities, or possess) or propose to handle eluxadoline.

100 项与 Pyrimidine series PROTACs 9(GlaxoSmithKline) 相关的药物交易

登录后查看更多信息